Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis
Monika A. Izano(Syndicat des Sélectionneurs Avicoles et Aquacoles Français), Shirish M. Gadgeel(Chinese University of Hong Kong), Jonathan Treisman(Ascension), Anand Patel(Ascension), Bindu Potugari(Henry Ford Health System), James L. Weese(Penn Presbyterian Medical Center), Andrew Stafford, Chenan Zhang, Douglas J. Reding(Ascension), Mary Tran, Frank M. Wolf, Thomas D. Brown, Connor Sweetnam
Cited by 10
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k